Immunology startup Clasp Therapeutics announced their launch with an impressive $150 million funding. Ex-Surface Bluebird executive Robert Ross, will be the CEO at the helm. Fresh off his stint at Surface Oncology, Ross was intrigued by the promise of Clasp and was eager to join their team.

Clasp Therapeutics has dual headquarters in Cambridge, Mass., and Rockville, Md. The company is focusing on the development of a new type of T-cell engager, developed by Johns Hopkins researchers Bert Vogelstein and Drew Pardoll. This project has drawn significant investment, with the biotech company successfully raising $150 million. This capital was led by notable players including Catalio Capital Management, Third Rock Ventures, and Novo Holdings.

Significantly, this funding means that Clasp can proceed with their clinical trials. The funds will be enough to support their entry into clinical trials and the collection of early proof-of-concept clinical data. This milestone is noteworthy and sets the stage for exciting developments in the future.

Source: Immuno-oncology startup Clasp Therapeutics launches with $150 million.